Published in Cardiovasc Drugs Ther on February 01, 2015
Retracted The improvement of large High-Density Lipoprotein (HDL) particle levels, and presumably HDL metabolism, depend on effects of low-carbohydrate diet and weight loss. EXCLI J (2016) 1.44
Association of Circulating IGFBP1 Level with the Severity of Coronary Artery Lesions in Patients with Unstable Angina. Dis Markers (2017) 0.75
Effect of Switching From Statin Monotherapy to Ezetimibe/Simvastatin Combination Therapy Compared With Other Intensified Lipid-Lowering Strategies on Lipoprotein Subclasses in Diabetic Patients With Symptomatic Cardiovascular Disease. J Am Heart Assoc (2015) 0.75
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol (2003) 5.77
Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA (2006) 4.90
AACE comprehensive diabetes management algorithm 2013. Endocr Pract (2013) 4.88
Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med (2006) 3.90
ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the CAPTIVATE randomized trial. JAMA (2009) 3.33
American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary. Endocr Pract (2013) 2.97
Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med (2003) 2.56
Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol (2005) 2.16
Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol (2006) 2.07
Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis (2007) 1.93
Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin. J Am Coll Cardiol (2006) 1.76
Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD. Am J Kidney Dis (2009) 1.68
Rationale, design, and implementation of aggressive risk factor management in the Stenting and Aggressive Medical Management for Prevention of Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) trial. Circ Cardiovasc Qual Outcomes (2012) 1.63
Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Curr Med Res Opin (2006) 1.53
Controversy surrounding the safety of cerivastatin. Expert Opin Drug Saf (2002) 1.50
High-density lipoproteins: a consensus statement from the National Lipid Association. J Clin Lipidol (2013) 1.50
Hypertriglyceridemic waist phenotype predicts increased visceral fat in subjects with type 2 diabetes. Diabetes Care (2009) 1.43
Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study). Am J Cardiol (2008) 1.43
Aace/Ace comprehensive diabetes management algorithm 2015. Endocr Pract (2015) 1.43
Relationship of abdominal visceral and subcutaneous adipose tissue with lipoprotein particle number and size in type 2 diabetes. Diabetes (2008) 1.41
The editor's roundtable: JUPITER follow-up. Am J Cardiol (2011) 1.39
Statin safety: an assessment using an administrative claims database. Am J Cardiol (2006) 1.22
Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study. Atherosclerosis (2008) 1.22
Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. Am J Cardiol (2008) 1.21
The use of high-sensitivity assays for C-reactive protein in clinical practice. Nat Clin Pract Cardiovasc Med (2008) 1.21
Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. Expert Rev Cardiovasc Ther (2008) 1.20
Relation of abdominal fat depots to systemic markers of inflammation in type 2 diabetes. Diabetes Care (2009) 1.20
Physical training improves insulin resistance syndrome markers in obese adolescents. Med Sci Sports Exerc (2002) 1.19
Effects of a reduced-glycemic-load diet on body weight, body composition, and cardiovascular disease risk markers in overweight and obese adults. Am J Clin Nutr (2007) 1.18
Diagnosis and treatment of familial hypercholesterolaemia. Eur Heart J (2013) 1.13
Individual variation in macronutrient regulation measured by proton magnetic resonance spectroscopy of human plasma. Am J Physiol Regul Integr Comp Physiol (2009) 1.08
Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme. Clin Drug Investig (2008) 1.07
Relationship of traditional and nontraditional cardiovascular risk factors to coronary artery calcium in type 2 diabetes. Diabetes (2007) 1.03
Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study. Am J Cardiovasc Drugs (2008) 1.02
Is LDL-C passed its prime? The emerging role of non-HDL, LDL-P, and ApoB in CHD risk assessment. Arterioscler Thromb Vasc Biol (2008) 1.01
Children with NAFLD are more sensitive to the adverse metabolic effects of fructose beverages than children without NAFLD. J Clin Endocrinol Metab (2012) 1.01
Contemporary awareness and understanding of cholesterol as a risk factor: results of an American Heart Association national survey. Arch Intern Med (2003) 1.00
Effects of oral and intravenous fat load on blood pressure, endothelial function, sympathetic activity, and oxidative stress in obese healthy subjects. Am J Physiol Endocrinol Metab (2010) 0.99
A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial). Clin Ther (2013) 0.97
Heritability of carotid intima-media thickness: a twin study. Atherosclerosis (2007) 0.97
Omega-3 fatty acid concentrates in the treatment of moderate hypertriglyceridemia. Expert Opin Pharmacother (2008) 0.94
The differential effect of statins on oxidative stress and endothelial function: atorvastatin versus pravastatin. J Clin Lipidol (2011) 0.94
Type 2 diabetes and cardiovascular disease: reducing the risk. J Manag Care Pharm (2007) 0.93
Cholesterol-lowering drugs bring benefits to high-risk populations even when LDL is normal. J Cardiovasc Nurs (2003) 0.92
Clinical significance of statin pleiotropic effects: hypotheses versus evidence. Circulation (2005) 0.92
Apolipoprotein C-III protein concentrations and gene polymorphisms in Type 1 diabetes: associations with microvascular disease complications in the DCCT/EDIC cohort. J Diabetes Complications (2005) 0.92
Concomitant use of statins and CYP3A4 inhibitors in administrative claims and electronic medical records databases. J Clin Lipidol (2008) 0.91
Atherogenic lipid profiles in Filipino adolescents with low body mass index and low dietary fat intake. Am J Hum Biol (2003) 0.91
Underappreciated opportunities for low-density lipoprotein management in patients with cardiometabolic residual risk. Atherosclerosis (2010) 0.91
Substitution of standard soybean oil with olive oil-based lipid emulsion in parenteral nutrition: comparison of vascular, metabolic, and inflammatory effects. J Clin Endocrinol Metab (2011) 0.91
Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin. Am J Cardiol (2003) 0.91
Evaluation of a novel colorimetric assay for free oxygen radicals as marker of oxidative stress. Clin Biochem (2008) 0.90
Consumption of diacylglycerol oil as part of a reduced-energy diet enhances loss of body weight and fat in comparison with consumption of a triacylglycerol control oil. Am J Clin Nutr (2002) 0.89
Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Expert Opin Drug Saf (2015) 0.89
A review of lipid management in primary and secondary prevention. J Cardiopulm Rehabil Prev (2009) 0.88
Lipid responses to a dietary docosahexaenoic acid supplement in men and women with below average levels of high density lipoprotein cholesterol. J Am Coll Nutr (2005) 0.88
Cholesterol absorption blockade with ezetimibe. Curr Drug Targets Cardiovasc Haematol Disord (2005) 0.87
Efficacy and safety of fenofibric acid in combination with a statin in patients with mixed dyslipidemia: Pooled analysis of three phase 3, 12-week randomized, controlled studies. J Clin Lipidol (2009) 0.87
Prognostic value of normal regadenoson stress perfusion cardiovascular magnetic resonance. J Cardiovasc Magn Reson (2013) 0.86
Relations of body fatness and cardiovascular fitness to lipid profile in black and white adolescents. Pediatr Res (2005) 0.86
Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials. Am J Cardiovasc Drugs (2010) 0.86
Cardiovascular Complications in CKD Patients: Role of Oxidative Stress. Cardiol Res Pract (2011) 0.86
High-density lipoproteins: marker of cardiovascular risk and therapeutic target. J Clin Lipidol (2010) 0.86
Predictors of anterior and posterior wall carotid intima media thickness progression in men and women at moderate risk of coronary heart disease. J Clin Lipidol (2011) 0.85
Adolescent diet and metabolic syndrome in young women: results of the Dietary Intervention Study in Children (DISC) follow-up study. J Clin Endocrinol Metab (2011) 0.85
Use of a treatment algorithm to achieve NCEP ATP III goals with atorvastatin. J Cardiovasc Pharmacol (2005) 0.85
Ethnic differences in achievement of cholesterol treatment goals. Results from the National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology II. J Gen Intern Med (2006) 0.85
Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study). Am J Cardiol (2011) 0.85
A sulfur amino acid-free meal increases plasma lipids in humans. J Nutr (2011) 0.85
Lp-PLA2: A new target for statin therapy. Curr Atheroscler Rep (2010) 0.84
Opportunities for using lipoprotein subclass profile by nuclear magnetic resonance spectroscopy in assessing insulin resistance and diabetes prediction. Metab Syndr Relat Disord (2012) 0.84
Comparison of the efficacy and safety of a combination tablet of niacin extended-release and simvastatin with simvastatin 80 mg monotherapy: the SEACOAST II (high-dose) study. J Clin Lipidol (2008) 0.84
Reduced treatment success in lipid management among women with coronary heart disease or risk equivalents: results of a national survey. Am Heart J (2006) 0.84
RE: Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. J Natl Cancer Inst (2014) 0.83
A randomized trial of an acid-peptic disease management program in a managed care environment. Am J Manag Care (2003) 0.83
Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the Comparative HDL Efficacy and Safety Study (CHESS). Am Heart J (2003) 0.83
Simvastatin improved arterial compliance in high-risk patients. Vasc Endovascular Surg (2004) 0.82
Effects of high-fiber oat and wheat cereals on postprandial glucose and lipid responses in healthy men. Int J Vitam Nutr Res (2007) 0.82
Evidence for altered positional specificity of LCAT in vivo: studies with docosahexaenoic acid feeding in humans. J Lipid Res (2004) 0.82
Reduced arterial compliance in patients with psychiatric diagnoses. Schizophr Res (2012) 0.82
A comparison of Canadian and American guidelines for lipid management using data from the National Cholesterol Education Program Evaluation ProjecT Utilizing Novel E-technology (NEPTUNE) II survey. Can J Cardiol (2006) 0.82
Pharmacokinetic interactions between statins and fibrates. Am J Cardiol (2005) 0.82
Usefulness of increased skin cholesterol to identify individuals at increased cardiovascular risk (from the Predictor of Advanced Subclinical Atherosclerosis study). Am J Cardiol (2008) 0.81
Carotid adventitial vasa vasorum and intima-media thickness in a primary prevention population. Echocardiography (2014) 0.81
Simvastatin plus ezetimibe: combination therapy for the management of dyslipidaemia. Expert Opin Pharmacother (2005) 0.81
Baseline lipoprotein lipids and low-density lipoprotein cholesterol response to prescription omega-3 acid ethyl ester added to Simvastatin therapy. Am J Cardiol (2010) 0.81
Flushing ASsessment Tool (FAST): psychometric properties of a new measure assessing flushing symptoms and clinical impact of niacin therapy. Clin Drug Investig (2009) 0.81
Non-high-density lipoprotein cholesterol: the forgotten therapeutic target. Am J Cardiol (2005) 0.81
Pioglitazone-mediated changes in lipoprotein particle composition are predicted by changes in adiponectin level in type 2 diabetes. J Clin Endocrinol Metab (2011) 0.80
Free oxygen radicals in whole blood correlate strongly with high-sensitivity C-reactive protein. J Clin Lipidol (2007) 0.80
Reducing the residual risk of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor therapy with combination therapy. Am J Cardiol (2008) 0.80
Apolipoprotein C-III protein concentrations and gene polymorphisms in type 1 diabetes: associations with lipoprotein subclasses. Metabolism (2004) 0.80
Effects of simvastatin, an HMG-CoA reductase inhibitor, in patients with hypertriglyceridemia. Clin Cardiol (2003) 0.79
Comparison of low-density lipoprotein cholesterol reduction after switching patients on other statins to rosuvastatin or simvastatin in a real-world clinical practice setting. Am J Manag Care (2007) 0.79
Peripheral artery disease, biomarkers, and darapladib. Am Heart J (2011) 0.79
The editor's roundtable: the JUPITER trial--initial results and clinical implications. Am J Cardiol (2009) 0.79